Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biohaven Pharmaceutical Holding Company Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,250,774
  • Shares Outstanding, K 44,263
  • Annual Sales, $ 0 K
  • Annual Income, $ -240,920 K
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -1.35
  • Number of Estimates 5
  • High Estimate -1.10
  • Low Estimate -1.64
  • Prior Year -2.32
  • Growth Rate Est. (year over year) +41.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.43 +17.08%
on 02/28/19
53.66 -5.24%
on 03/22/19
+5.85 (+13.00%)
since 02/22/19
3-Month
29.17 +74.32%
on 12/24/18
53.66 -5.24%
on 03/22/19
+21.10 (+70.92%)
since 12/21/18
52-Week
16.50 +208.18%
on 03/26/18
53.66 -5.24%
on 03/22/19
+23.64 (+86.88%)
since 03/22/18

Most Recent Stories

More News
Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric...

BHVN : 50.85 (-4.58%)
Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric...

BHVN : 50.85 (-4.58%)
Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric...

BHVN : 50.85 (-4.58%)
Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Expedia Group, Inc. (NASDAQ:EXPE),...

BHVN : 50.85 (-4.58%)
PDCO : 22.28 (-2.32%)
EXPE : 121.64 (-1.98%)
MDRX : 9.90 (-6.07%)
ATRC : 28.00 (-2.10%)
LITE : 52.84 (+1.42%)
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting central nervous system diseases,...

BHVN : 50.85 (-4.58%)
What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?

Does Biohaven Pharmaceutical Holding Company Ltd. (BHVN) have what it takes to be a top stock pick for momentum investors? Let's find out.

BHVN : 50.85 (-4.58%)
Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today that it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate...

BHVN : 50.85 (-4.58%)
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal...

BHVN : 50.85 (-4.58%)
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and its wholly-owned Asia-Pacific subsidiary company, BioShin, announced today the National Medical Products Administration ("NMPA")...

BHVN : 50.85 (-4.58%)
Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock?

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

BHVN : 50.85 (-4.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BHVN with:

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

2nd Resistance Point 54.76
1st Resistance Point 52.81
Last Price 50.85
1st Support Level 49.75
2nd Support Level 48.64

See More

52-Week High 53.66
Last Price 50.85
Fibonacci 61.8% 39.46
Fibonacci 50% 35.08
Fibonacci 38.2% 30.70
52-Week Low 16.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar